查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1606625

限制性胜肽藥物市場：按胜肽類型、最終用戶分類 - 全球預測 2025-2030

Constrained Peptide Drugs Market by Peptide Type (Macrocyclic, Stapled), End-User (Hospitals & Clinics, Pharmaceutical Companies) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年限制性胜肽藥物市場價值為12.2億美元，預計到2024年將達到14.7億美元，複合年成長率為21.44%，到2030年將達到47.6億美元。

限制性胜肽藥物是生物技術療法的創新子集，涉及化學或結構限制，因此與傳統胜肽相比具有增強的穩定性和特異性。這一快速成長的領域至關重要，因為它有可能透過針對細胞內以前被認為「無法治療」的蛋白質-蛋白質相互作用來解決未滿足的醫療需求。其應用涵蓋腫瘤學、代謝疾病和自體免疫疾病，在這些治療領域具有廣泛的最終用途。市場成長是由研發投資的增加、胜肽合成技術的進步以及標靶疾病的增加所推動的。特別是，這些藥物的精確度和功效為個人化醫療提供了巨大潛力，進一步推動了需求。

主要市場統計
基準年[2023] 12.2億美元
預測年份 [2024] 14.7億美元
預測年份 [2030] 47.6億美元
複合年成長率（%） 21.44%

最近的機會來自技術進步，例如藥物發現中的人工智慧，可以簡化可行的受限胜肽的識別，以及生物技術公司和學術界之間促進創新的策略聯盟。公司應該投資這些夥伴關係和先進的計算工具，以保持競爭力。然而，挑戰依然存在，包括高昂的開發和製造成本、嚴格的監管要求以及擴大胜肽藥物生產的固有複雜性。

創新應著重於改進合成技術，例如固相胜肽合成（SPPS）以及與小分子和生技藥品的雜合反應，以改善藥物特性。此外，探索新的標靶和遞送系統可以擴大限制胜肽的應用範圍。

市場極為活躍，併購導致競爭日益激烈。最佳策略包括繼續參與合作研究計劃並利用最尖端科技進行藥物設計。在利用這些機會的同時，企業應致力於有效地掌握監管發展動態，以縮短上市時間並確保永續成長和市場領導地位。平衡開創性藥物開發的投資和克服物流限制對於釋放限制性胜肽藥物市場的潛力至關重要。

市場動態：揭示快速發展的限制性胜肽藥物市場的關鍵市場洞察

供應和需求的動態交互作用正在改變限制性胜肽藥物市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 世界慢性病的增加
    • 胜肽化學和合成技術的不斷進步
    • 對製造生技藥品和個人化藥物的需求增加
  • 市場限制因素
    • 與胜肽藥物開發相關的高成本
  • 市場機會
    • 加強研發力度，開發新型限制性胜肽藥物
    • 政府對包括限制性胜肽藥物在內的創新治療方法的支持
  • 市場問題
    • 多肽生物利用度低的問題

波特五力：駕馭限制性胜肽藥物市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解限制性多肽藥物市場的外部影響

外部宏觀環境因素在塑造限制性胜肽藥物市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析：了解限制性胜肽藥物市場的競爭格局

對限制性胜肽藥物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來發現自己的競爭定位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：限制性胜肽藥物市場供應商的績效評估

FPNV定位矩陣是評估限制性胜肽藥物市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：在限制性胜肽藥物市場中製定成功之路

對於旨在加強其在全球市場的影響力的公司來說，限制性胜肽藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1. 市場滲透率：對當前市場環境的詳細審查，主要企業的廣泛資料，評估他們在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3. 塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球慢性病發生率正在上升
      • 胜肽化學和合成技術的不斷進步
      • 對生物製藥和個人化藥品製造的需求不斷成長
    • 抑制因素
      • 與胜肽藥物開發相關的高成本
    • 機會
      • 加強限制性胜肽藥物新開發研發
      • 政府對創新治療方法的支持（包括限制性胜肽藥物）
    • 任務
      • 胜肽生物有效性低所引起的問題
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章 限制性多肽藥物市場：按多肽類型

  • 介紹
  • 大環
  • 吻合術

第7章 限制性胜肽藥物市場：依最終使用者分類

  • 介紹
  • 醫院/診所
  • 製藥公司

第8章 北美和南美限制性多肽藥物市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太限制性多肽藥物市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲限制性多肽藥物市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Bicycle Therapeutics, Inc.
  • Biosynth Ltd
  • IRBM SpA
  • PeptiDream Co., Ltd.
  • Pfizer Inc.
  • Protagonist Therapeutics, Inc.
  • UCB SA
Product Code: MRR-5C6F41F5AF46

The Constrained Peptide Drugs Market was valued at USD 1.22 billion in 2023, expected to reach USD 1.47 billion in 2024, and is projected to grow at a CAGR of 21.44%, to USD 4.76 billion by 2030.

Constrained peptide drugs are an innovative subset of biotechnology therapeutics characterized by their enhanced stability and specificity compared to traditional peptides, due to the inclusion of chemical or structural constraints. This burgeoning segment is vital due to its potential to address unmet medical needs by targeting challenging intracellular protein-protein interactions, previously deemed "undruggable." Their applications span oncology, metabolic disorders, and autoimmune diseases, providing significant end-use scope in these therapeutic areas. Market growth is fueled by rising investments in R&D, advancements in peptide synthesis technologies, and increasing prevalence of targeted diseases. Notably, the precision and potency of these drugs offer substantial promise in personalized medicine, further driving demand.

KEY MARKET STATISTICS
Base Year [2023] USD 1.22 billion
Estimated Year [2024] USD 1.47 billion
Forecast Year [2030] USD 4.76 billion
CAGR (%) 21.44%

Recent opportunities arise from technological advancements such as artificial intelligence in drug discovery, which can streamline the identification of viable constrained peptides, and strategic collaborations between biotech firms and academia, facilitating innovation. Companies should invest in these partnerships and advanced computational tools to stay competitive. However, challenges persist, primarily the high cost of development and production, stringent regulatory requirements, and the inherent complexity of scaling peptide drug manufacturing.

Innovation should focus on improving synthesis techniques, such as solid-phase peptide synthesis (SPPS) and hybridization with small molecules or biologics to enhance drug properties. Moreover, exploring novel targets and delivery systems can expand the applicability of constrained peptides.

The market is highly dynamic, with a landscape marked by competitive consolidation through mergers and acquisitions. The best strategy involves continuous engagement in collaborative research initiatives and leveraging cutting-edge technologies for drug design. While capitalizing on these opportunities, companies should also aim to navigate regulatory pathways efficiently to reduce time-to-market, ensuring sustained growth and market leadership. Balancing investment between pioneering drug development and overcoming logistical limitations will be crucial for seizing the potential within the constrained peptide drugs market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Constrained Peptide Drugs Market

The Constrained Peptide Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidences of chronic diseases globally
    • Continuous advancements in peptide chemistry and synthesis techniques
    • Increasing demand for manufacturing of biologics and personalized medicines
  • Market Restraints
    • High cost associated with the drug development of peptides
  • Market Opportunities
    • Increasing research & development to develop novel constrained peptide drugs
    • Availability of government support for innovative therapies, including constrained peptide drugs
  • Market Challenges
    • Issues with low bioavailability of peptides

Porter's Five Forces: A Strategic Tool for Navigating the Constrained Peptide Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Constrained Peptide Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Constrained Peptide Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Constrained Peptide Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Constrained Peptide Drugs Market

A detailed market share analysis in the Constrained Peptide Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Constrained Peptide Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Constrained Peptide Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Constrained Peptide Drugs Market

A strategic analysis of the Constrained Peptide Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Constrained Peptide Drugs Market, highlighting leading vendors and their innovative profiles. These include Bicycle Therapeutics, Inc., Biosynth Ltd, IRBM S.p.A., PeptiDream Co., Ltd., Pfizer Inc., Protagonist Therapeutics, Inc., and UCB S.A.

Market Segmentation & Coverage

This research report categorizes the Constrained Peptide Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Peptide Type, market is studied across Macrocyclic and Stapled.
  • Based on End-User, market is studied across Hospitals & Clinics and Pharmaceutical Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of chronic diseases globally
      • 5.1.1.2. Continuous advancements in peptide chemistry and synthesis techniques
      • 5.1.1.3. Increasing demand for manufacturing of biologics and personalized medicines
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with the drug development of peptides
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing research & development to develop novel constrained peptide drugs
      • 5.1.3.2. Availability of government support for innovative therapies, including constrained peptide drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Issues with low bioavailability of peptides
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Constrained Peptide Drugs Market, by Peptide Type

  • 6.1. Introduction
  • 6.2. Macrocyclic
  • 6.3. Stapled

7. Constrained Peptide Drugs Market, by End-User

  • 7.1. Introduction
  • 7.2. Hospitals & Clinics
  • 7.3. Pharmaceutical Companies

8. Americas Constrained Peptide Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Constrained Peptide Drugs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Constrained Peptide Drugs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Bicycle Therapeutics, Inc.
  • 2. Biosynth Ltd
  • 3. IRBM S.p.A.
  • 4. PeptiDream Co., Ltd.
  • 5. Pfizer Inc.
  • 6. Protagonist Therapeutics, Inc.
  • 7. UCB S.A

LIST OF FIGURES

  • FIGURE 1. CONSTRAINED PEPTIDE DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. CONSTRAINED PEPTIDE DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. CONSTRAINED PEPTIDE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. CONSTRAINED PEPTIDE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CONSTRAINED PEPTIDE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CONSTRAINED PEPTIDE DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY MACROCYCLIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY STAPLED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. AMERICAS CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 16. ARGENTINA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 18. BRAZIL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. CANADA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. MEXICO CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. UNITED STATES CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 27. ASIA-PACIFIC CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. AUSTRALIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. CHINA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. INDIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. INDONESIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. JAPAN CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. MALAYSIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. PHILIPPINES CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. SINGAPORE CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. SOUTH KOREA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. TAIWAN CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. THAILAND CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. VIETNAM CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. DENMARK CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. EGYPT CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. FINLAND CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. FRANCE CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. GERMANY CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. ISRAEL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. ITALY CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. NETHERLANDS CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. NIGERIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. NORWAY CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. POLAND CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. QATAR CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. RUSSIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. SAUDI ARABIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH AFRICA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SPAIN CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. SWEDEN CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. SWITZERLAND CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. TURKEY CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED ARAB EMIRATES CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED KINGDOM CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. CONSTRAINED PEPTIDE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 100. CONSTRAINED PEPTIDE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023